Adam Feuerstein weighs in (video) on the upcoming FDA decision on a lung inhaler from Alexza...


Adam Feuerstein weighs in (video) on the upcoming FDA decision on a lung inhaler from Alexza Pharmaceuticals (ALXA +0.8%), saying that an approval is "not a sure bet" and is too close to call. Trading volume in ALXA spiked higher after the biotech analyst's comments were distributed and digested, although shares only traced up moderately.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs